epic:phase 3 trial of ponatinib compared with imatinib in newly diagnosed chronic myeloid leukemia
Published 9 years ago • 525 plays • Length 2:50Download video MP4
Download video MP3
Similar videos
-
2:50
epic:phase 3 trial of ponatinib compared with imatinib in newly diagnosed chronic myeloid leukemia
-
3:31
ash 2021: new optic trial analysis shows ponatinib is effective in chronic myeloid leukemia patients
-
1:35
safety of ponatinib in chronic-phase chronic myeloid leukemia (cml) patients
-
5:22
bosutinib versus ponatinib in r/r cml
-
2:49
outcomes of patients with cml-cp treated with ponatinib vs 2g-tkis in the third-line setting
-
1:40
using ponatinib to treat highly resistant chronic myeloid leukemia, results from a phase i trial
-
2:12
5-year update of bfore: bosutinib vs imatinib in cml
-
4:19
optic: ponatinib in resistant chronic-phase cml
-
7:47
is ponatinib safe for treating cml?
-
24:30
management of thrombosis risk with ponatinib and other tkis for cml?
-
6:53
results of the phase iii dasision trial and the future of cml treatment
-
1:01
dr. cortes discusses ponatinib as initial therapy for cml
-
8:12
treatment selection for resistant or intolerant chronic myeloid leukemia
-
1:10
final results of the bfore trial: bosutinib vs imatinib in cp-cml
-
2:06
dr. jorge cortes discusses the ponatinib ph all and cml evaluation (pace) trial
-
4:18
ponatinib efficacy and safety with the t315i mutation: long-term follow-up of phase 1&2 trials
-
3:51
interim data analysis suggests ponatinib to be favorable tki treatment among cml patients
-
8:00
dr. cortes discusses approval of ponatinib for adults with chronic-phase cml
-
7:42
ponatinib: promises and challenges